For the first quarter, Pacira BioSciences reported record sales of Exparel, a non-opioid pain management drug that became eligible for separate Medicare reimbursement in ASCs as of Jan. 1.
Three quick insights:
1. Net sales of Exparel reached $90.6 million in the first quarter of 2019, a year-over-year increase of 22.4 percent.
2. ASCs and oral surgery centers were the key drivers of Exparel utilization.
3. Pacira's total first-quarter revenues were $91.3 million, up from $74.6 million in the first quarter of 2018.